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Summary
Objective: We have shown previously that cutting or loading articular cartilage resulted in a ﬁbroblast growth factor-2 (FGF-2) dependent
activation of the extracellularly regulated kinase (ERK), and induction of a number of chondrocyte regulatory proteins including tissue inhibitor
of metalloproteinase-1 and matrix metalloproteinases 1 and 3. An extracellular matrix-bound pool of FGF-2 was apparent, which could be
liberated from the tissue by heparitinase (Vincent et al., Proc Natl Acad Sci U S A 2002;99(12):8259e64, Vincent et al., Arthritis Rheum
2004 Feb;50(2):526e33). Our objectives were to determine where FGF-2 was stored in articular cartilage, to which proteoglycan it was bound,
and to elucidate its role in chondrocyte mechanotransduction.
Methods: Immunohistochemistry and confocal microscopy were used to localise FGF-2 in the tissue. In vitro binding studies were performed
using IASYS surface plasmon resonance. To study the role of pericellular FGF-2 in mechanotransduction cartilage explants or articular chon-
drocytes encapsulated in alginate were loaded using an in house loading rig. The loading response was assessed by the activation of ERK, in
the presence or absence of a speciﬁc FGFR inhibitor.
Results: Here we have identiﬁed perlecan as the heparan sulphate proteoglycan that sequesters FGF-2 in articular cartilage. Perlecan and
FGF-2 co-localised within the type VI collagen-rich pericellular matrix of porcine and human articular cartilage. Chondrocytes encapsulated
in alginate were able to accumulate pericellular perlecan and FGF-2 in culture, and deliver an FGF-dependent activation of ERK when loaded.
Conclusion: Loading-induced ERK activation was dependent upon the presence and concentration of pericellular FGF-2, suggesting a func-
tional role for this matrix-bound growth factor in chondrocyte mechanotransduction.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
Key words: Basic ﬁbroblast growth factor, Perlecan, Pericellular matrix, Mechanotransduction.
Abbreviations: FGF-2 basic ﬁbroblast growth factor, HS heparan sulphate, CS chondroitin sulphate, PG proteoglycan, GAG glycosamino-
glycan, pERK phosphorylated extracellularly regulated kinase.
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The ability of the cells of articular cartilage to sense and re-
spond to mechanical force is undisputed. Not only is it well
accepted that excessive mechanical stress increases the
risk of developing osteoarthritis, but intermittent loads asso-
ciated with modest weight bearing activity appear to be im-
portant for anabolic tissue responses. This is illustrated by
the observation that 50% of knee cartilage volume is lost
in patients within 6 months of sustaining a spinal cord in-
jury1, and a recent imaging study in which patients, rando-
mised to moderate exercise, demonstrated increased
glycosmaninoglycan (GAG) content in their knee cartilage
using delayed gadolinium-enhanced magnetic resonance
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data showing regulation in vitro of matrix proteins such as
aggrecan and type II collagen, as well as matrix metallopro-
teinases (MMPs) and tissue inhibitors of metalloproteinases
(TIMPs), in response to loading cartilage explants and
chondrocytes3e7. It should be stressed that regulation is
complex, and is affected by the frequency, magnitude and
duration of the applied load8e10.
Surprisingly little is known about how mechanical signals
are transduced through cartilage to change chondrocyte
gene expression. Integrins are favoured mechanical trans-
ducers in cartilage: through their extracellular domains
they form multiple connections with the extracellular matrix
(reviewed in Ref.11), and intracellularly, they are thought to
recruit signalling molecules (they have no intrinsic signalling
activity themselves) to activate signalling pathways12e14. In-
deed, hyperpolarisation of human articular chondroctyes in
response to stretch, and a transforming growth factor (TGF)
beta-dependent incorporation of 35SO4 in compressed
monolayer chondrocytes were both inhibited by alpha 5
beta 1 integrin blockade15e17.
Intracellular signalling events in response to loading
chondrocytes also include activation of ion- and stretch-2
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tected in chondrocytes in agarose in response to
cyclical load18, and blocking stretch-activated channels,
and calcium ﬂux with gadolinium or nifedipine, respectively,
inhibited the biological responses to stretch of primary
chondrocytes seeded in a collagen matrix19. Voltage-
activated calcium channels and epithelial sodium channels
have been shown to co-localise with beta 1 integrin in
‘mechanoreceptor complexes’ in loaded limb bud
chondrocytes20.
It is also possible that tissue growth factors act as mecha-
notransducers. Previously, we found that there was an
ﬁbroblast growth factor (FGF)-dependent activation of the
extracellularly regulated kinase (ERK) upon cutting or load-
ing articular cartilage7,21. FGF-2 was present in the extra-
cellular matrix of articular cartilage and was released
following treatment with the heparin degrading enzyme hep-
aritinase, suggesting that it was bound to a heparan sul-
phate proteoglycan (HSPG). Perlecan, originally described
as the proteoglycan of basement membranes, is highly ex-
pressed in cartilage22e24 and is therefore a good candidate
for sequestering FGF-2.
We hypothesised that in articular cartilage FGF-2 is
stored in the extracellular matrix bound to perlecan, and
that it is this pool of FGF that mediates FGF receptor
activation upon mechanical stimulation. Here we show
that perlecan is an abundant HSPG in human articular
cartilage, and that perlecan and FGF-2 co-localise within
the pericellular matrix of articular cartilage. Activation of
ERK in loaded alginate encapsulated chondrocytes is de-
pendent upon the presence and concentration of peri-
cellular FGF-2.
Methods
TISSUE
Porcine articular cartilage was from the metacarpopha-
langeal joints, and knee joints of 3- to 6-month-old pigs
obtained from a local abattoir 4e8 h post-slaughter.
Normal human articular cartilage was from the knee
joint of individuals (ages 55 and 60 years) undergoing
surgery at the RNOH, Stanmore, for removal of bone
tumours.
MATERIALS
Antibodies to perlecan (rat monoclonal, MAB1948) were
obtained from Chemicon International (Temecla, CA).
FGF-2 antibodies (mouse monoclonal, 05-118), and phos-
photyrosine clone 4G10 were from Upstate Cell signalling
solutions, Milton Keynes. Collagen type VI anti-serum (rab-
bit) was kindly provided by Thomas Aigner, Erlangen, Ger-
many. Monoclonal antibodies to beta 1 integrin were
purchased from Biohit, Helsinki, Finland. Basic FGF was ob-
tained from Peprotec, London, insulin growth factor (IGF)-1
was from R and D Systems, MN. Heparitinase I, Chondroiti-
nase ABC and the heparan sulphate (HS) stub antibody
(3G10) (Seikagaku, Japan) were purchased through Calbio-
chem, Nottingham, UK. For heparitinase, enzyme was re-
constituted upon arrival, aliquotted, then re-lyophilised and
stored at 70C until required. SB402451 (also known as
PD173074)41 was kindly provided by Stephen Skaper,
Glaxo Wellcome. All other reagents including hyaluronidase
and Insulin Transferrin Selenium (ITS)þ 1 liquid media were
purchased from Sigma, UK.CONFOCAL MICROSCOPY
Six-micrometre frozen sections were cut onto Surgipath
snowcoat Xtra slides, air dried for 1 h and then left for a fur-
ther hour at 60C to ensure tissue adherence. Slides were
ﬁxed in acetone for 10 min. Sections were pre-treated with
hyaluronidase for 1 h (0.01% hyaluronidase/tris-buffered
saline at 37C) with or without heparitinase (10 mu/ml),
blocked with 5% bovine serum albumin/1% goat serum/
phosphate-buffered saline (PBS) for 1 h at 37C, then incu-
bated for a further 1 h at 37C with antibodies to perlecan
(1:1000), FGF-2 (1:1000), type VI collagen (1:5000), beta 1
integrin (1:1000), heparan sulphate stub (3G10) (1:1000)
either alone or in combination. Sections were washed with
PBS three times, then incubated for 1 h with secondary
ﬂuorescein iso-thiocyanate (FITC) labelled antibodies
(Alexa 488-conjugated anti-mouse IgG and Alexa 568-
conjugated anti-rat IgG). Sections were further washed
and mounted. Fluorescence signals were detected by Ultra-
view confocal microscopy (PerkineElmer, 60 oil immer-
sion lens).
IMMUNOHISTOCHEMISTRY
For perlecan/FGF-2 staining, 5-mm frozen sections were
prepared as above. Sections were blocked with 10% nor-
mal serum and were incubated with primary antibodies to
perlecan (1:1000) or FGF-2 (1:1000). Antigens were visual-
ised using streptavidin conjugated peroxidase (ABC kit,
Vector) according to the manufacturer’s recommendations.
IMMUNOSTAINING OF ALGINATE ENCAPSULATED
CHONDROCYTES
Ten alginate beads were dissolved in ethylenediaminete-
traacetic acid (EDTA) (100 ml, 50 mM), washed in NaCl
(150 mM) and then resuspended in NaCl (20 ml) and loaded
onto Lab-Tek II chamber slides (Nalge Nunc Int, Denmark).
The slide was air dried, ﬁxed in methanol for 15 min and
then stained as above.
PURIFICATION OF PERLECAN AND AGGRECAN
Perlecan and aggrecan were puriﬁed from batches of
10 g of articular knee cartilage. Tissue was dissected into
a 50-ml falcon and washed three times with sterile PBS.
A total of 30 ml of 6 M GnHCl was added to the tissue bring-
ing the volume up to 45 ml, and ﬁnal concentration to 4 M
GnHCl. Tissue was left rotating at 4C for 48 h. Insoluble
material was removed by centrifugation. Puriﬁcation was
as described by Govindraj et al.28, using dot blot to conﬁrm
position of proteins. From 10 g of starting material, assum-
ing 99% purity, 0.429 mg of perlecan and 56.42 mg of aggre-
can were obtained.
PLASMON SURFACE RESONANCE (IASYS)
This technique, similar to Biacore analysis, was used to
detect binding of heparan sulphate proteoglycan to immobi-
lised FGF-2. One microgram of basic FGF or IGF (control)
was covalently coupled to carboxymethyl dextran sensor
chips (Afﬁnity Sensors, Cambridge, UK). Remaining acti-
vated sites on the sensor surface were blocked with 1 M
Tris/HCl, pH 8.0. Bound levels of protein were calculated
to be between 1 and 6 ng/mm2. The cuvette was equili-
brated with PBS, and binding characteristics were observed
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molar concentrations (based on core MW). The cuvette
was washed with 4 M GnHCl brieﬂy between washes to dis-
sociate perlecan from FGF-2. Similar analyses were per-
formed on material that had been previously exchanged
into buffer (NaCl 150 mmol/CaCl2 5 mmol, pH 6.2), then
treated with either heparitinase (2 m/ml) or chondroitinase
ABC (10 m/ml) at 37C for 1 h.
ALGINATE ENCAPSULATED CHONDROCYTES
Chondrocytes were isolated from porcine metacarpopha-
langeal joints as previously described21. Cells were washed
in 150 mM NaCl then resuspended in 1.2% alginate (in
150 mM NaCl) at a density of 5 million cells per ml. The sus-
pension was drawn up into a 10 ml syringe and cells drop-
ped through a 25-gage needle into calcium chloride
(102 mM) to form beads. Beads were left to harden for
15 min, washed twice in Dulbecco’s Modiﬁed Eagle’s
Medium (DMEM) and then transferred to 24 well plates
(5 million cells per well/approximately 70 beads). The beads
were cultured in 10% foetal calf serum (FCS) for at least
3 weeks to allow matrix to be laid down. In some cultures,
FGF-2 (5 ng/ml) was added after 2 weeks for 3 days and
then washed out.
On the morning of the loading experiment, to create the
alginate ‘plug’, beads from individual wells were transferred
to Transwell Permeable Supports (pore size: 3.0 mm, diam-
eter 12 mm, Corning, Inc.) and immersed in 1.5 ml of cal-
cium chloride (102 mM) in 12 well plates. 1.2% alginate
(approx 300 ml) was added to the Transwell, and further cal-
cium chloride was added to the top of the well. Plugs were
left for 2 h at room temperature before removing them from
the Transwell and washing them back into serum-free
DMEM.
LOADING ALGINATE PLUGS AND CARTILAGE EXPLANTS
Alginate plugs were serum starved for 2 h prior to loading
in the presence or absence of the FGFR inhibitor,
SB402451 (48 h pre-incubation). Individual plugs were
placed between two polyethylene frits (100 mm pore,
15 mm diameter, Kinesis) in a 6 ml bijou and covered with
1 ml DMEM (with or without SB402451). Plugs were loaded
using a purpose build pneumatically driven loading rig (for
illustration see Fig. 1), from an original design by Richard
Aspden, Aberdeen4. The rig was housed within a humidiﬁed
incubator (37C, 20% O2, 5% CO2). In essence, loading
was achieved by compressed air which raised the lower
platform upon which the tissue samples were sitting and
in doing so lifted the loading rod with attached weights.
Load was thus transmitted through the tissue. The loading
waveform was square, but up and down ramp speeds
were slowed to so as to create a sinusoid-like waveform.
The loading rod was in contact with the tissue at the start
of the experiment, in order to minimise impact. Loads deliv-
ered to alginate plugs were low: 160 g (the weight of the
loading rod), which equated to 0.01 MPa. The amount of
strain measured following a 2 min cyclical load was in the
order of 25%. After 2 min of conﬁned loading (0.5 Hz) the
plug was maintained at 37C for 30 min and then was trans-
ferred onto ice. Medium was replaced with EDTA (50 mM in
150 mM NaCl with 2% Na3VO4) to dissolve the alginate.
Chondrocytes were centrifuged, washed with PBS, then
lysed with a dissociative lysis buffer containing protease
inhibitors as described previously7. For cartilage explants,tissue was loaded cyclically for 2 min with 1000 g, equating
to 0.13e0.2 MPa, depending upon the size of the explant
(25e49 mm2). The strain, as measured using a Draper ex-
ternal micrometer was approximately 5%. Tissue was left at
37C for 30 min then lysed as above. Lysates were immu-
noblotted for phosphoERK and reprobed for total ERK as
before21. Some plugs/explants were stimulated with re-
combinant FGF-2 (100 ng/ml), or with interleukin-1 (IL-1)
(100 ng/ml) for 30 min at 37C.
Results
PERLECAN IS AN ABUNDANT HSPG IN ADULT HUMAN
ARTICULAR CARTILAGE
Having previously established that FGF-2 was seques-
tered in the matrix of articular cartilage attached to HS21,
we sought to determine where the abundant HSPGs were
in the tissue. Human articular cartilage sections were ﬁrst
treated with either heparitinase or with control buffer for
1 h. Sections were stained with an antibody against the
HS stub generated by heparitinase treatment. Prior to treat-
ment with heparitinase (control), little in the way of immuno-
reactive material was detected in the extracellular matrix,
however, following treatment with heparitinase, strong
staining around individual chondrocytes was detected
[Fig. 2(A), HS stub, heparitinase treated]. Pericellular stain-
ing for the HS proteoglycan perlecan has been described in
a number of cartilaginous tissues including ovine stiﬂe joint
articular cartilage22e25. Staining the sections for perlecan
showed precise co-localisation of perlecan and the HS
stub by confocal microscopy, suggesting that perlecan
was the most abundant HSPG in articular cartilage. At
this level of detection, it was not possible to discern cell sur-
face HSPG distinct from perlecan [Fig. 2(A), Perlecan and
Merged].
To conﬁrm that perlecan was in the true pericellular ma-
trix, rather than on the cell surface or in the territorial matrix,
further confocal microscopy was performed. Immunostain-
ing for perlecan and a cell surface antigen, beta 1 integrin,
revealed distinct spatial separation with no evidence of co-
localisation [Fig. 2(B)], indicating that perlecan was indeed
Affixed weight
Medium
polyethylene frit
alginate plug
Fig. 1. Schematic representation of loading unit. The rig was
housed in a humidiﬁed incubator at 37C, 20% O2, 5% CO2. One
loading unit out of 6 is shown.
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C Perlecan Type VI collagen Merged
A HS stub Perlecan Merged
Control
Heparitinase
treated
Fig. 2. Localisation of HSPGs in articular cartilage. Six-micrometre frozen sections of human articular cartilage were pre-treated with hyaluron-
idase (0.01%, 1 h) with or without heparitinase (10 mu/ml for 1 h). Sections were stained with either the HS stub antibody 3G10 (1:1000) and
perlecan (1:1000) (A), with antibodies to perlecan (1:1000) and beta 1 integrin (1:1000) (B), or perlecan (1:1000) and type VI collagen (1:5000)
(C). Sections were washed and incubated with secondary FITC labelled antibodies (1:2000). Fluorescence signals were detected by Ultraview
confocal microscopy. Bar¼ 20 mm.outside the cell. Moreover, staining for perlecan and type VI
collagen, a known pericellular matrix protein26, revealed that
they only partly co-localised, but that both proteins lay within
the same anatomical matrix compartment [Fig. 2(C)].
FGF-2 CO-LOCALISES WITH PERLECAN IN HUMAN
ARTICULAR CARTILAGE
We next sought to determine whether FGF-2 and perlecan
co-localised in the pericellular matrix. Immunohistochemistryof adult femoral chondylar cartilage revealed a distinct
pattern of staining which was similar for both FGF-2 and
perlecan [Fig. 3(A)]. In the mid zone of cartilage, staining
for both was pericellular. Interestingly, in the superﬁcial
zone, perlecan and FGF-2 were distributed in a distinct
pattern where multiple cells were encompassed within
laminar bands of staining running parallel to the articular
surface. This superﬁcial pattern of staining was approxi-
mately six to eight cells deep from the articular surface
and was present in normal adult articular cartilage from
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Fig. 3. Immunolocalisation of FGF-2 and perlecan in human and porcine articular cartilage. Articular cartilage from adult human was snap
frozen and sectioned (5 mm). Sections were treated with hyaluronidase (0.01% for 1 h) then stained with an irrelevant antibody (control), or
with antibodies to FGF-2 (1:1000) or perlecan (1:1000). Antigens were visualised using the peroxidase based ABC kit (see Methods). Details
are shown from the superﬁcial and mid zones of cartilage (A). Bar¼ 100 mm. Five-micrometre sections of porcine metacarpophalangeal
articular cartilage were treated with hyaluronidase and immunostained as in (A) for FGF-2 and perlecan (B). Six-micrometre sections from
757Osteoarthritis and Cartilage Vol. 15, No. 7Fig. 4. Perlecan puriﬁed from articular cartilage binds FGF-2 in vitro. FGF-2 was coupled to the IASYS sensor surface (see Methods). 0.8 mg
(5 ml in 4 M GnHCl) of perlecan (solid line) or 1.6 mg (5 ml in 4 M GnHCl) of aggrecan (dashed line) was diluted in PBS (95 ml) and added to the
sensor surface. Binding (arc seconds) was observed (A). In a separate experiment, 0.8 mg of perlecan was exchanged into buffer (NaCl
150 mmol/CaCl2 5 mmol, pH 6.2) then incubated with either buffer alone or 2 mu/ml heparitinase for 1 h at 37
C. Buffer treated perlecan (solid
line), or heparitinase treated perlecan (dashed line) were added to the cuvette in PBS. Binding was observed when each sample (5 ml in 95 ml
PBS) was added to the cuvette sensor surface (B).other regions of the knee joint, both weight bearing and non
weight bearing (data not shown). Pericellular staining for
FGF-2 and perlecan was also present in porcine articular
cartilage although the laminar staining pattern in the super-
ﬁcial layer was not apparent [Fig. 3(B)]. By confocal micros-
copy perlecan and FGF-2 co-localised [Fig. 3(C)] in all
cartilage zones.
PERLECAN PURIFIED FROM PORCINE ARTICULAR CARTILAGE
BINDS TO RECOMBINANT FGF-2 IN VITRO
To verify the immunohistochemistry, perlecan was puri-
ﬁed from porcine articular cartilage (see Methods), and
surface plasmon resonance was used to determine that
it bound recombinant FGF-2 in vitro. Aggrecan puriﬁed
from articular cartilage was used as a negative control.
Both samples were immunoblotted to conﬁrm proteogly-
can purity (data not shown). Immobilised FGF-2 bound
to perlecan, but not to equimolar concentrations (by
core molecular weight) of aggrecan [Fig. 4(A)]. In a sepa-
rate experiment, binding was shown to be dependent
upon heparan sulphate as prior treatment of perlecan
with heparitinase abolished binding [Fig. 4(B)]. Some
loss of protein was apparent in the heparitinase and
buffer treated samples which most likely reﬂected losses
during buffer exchange. Prior treatment of perlecan with
chondroitinase did not affect binding to FGF-2 indicating
that the interaction between perlecan and FGF-2 was
mediated by heparan sulphate and not sulphated proteo-
glycan per se (data not shown).
ALGINATE ENCAPSULATED PORCINE CHONDROCYTES
ACCUMULATE PERICELLULAR PERLECAN AND FGF-2
To investigate the source and function of pericellular
FGF-2, we ﬁrst looked to see whether isolated porcine artic-
ular chondrocytes would accumulate a pericellular matrix in
culture. Porcine chondrocytes were encapsulated into algi-
nate beads, then cultured for 3 weeks in either 10% serum
or ITS, a synthetic serum substitute containing no FGF-2. Atthe end of the culture period, cells were released by dissolv-
ing the alginate, and immunostained for perlecan or FGF-2.
Freshly isolated chondrocytes, that had been cultured in
alginate for only 2 days had little detectable staining for
either perlecan or FGF-2 (Fig. 5, control), however, alginate
encapsulated cells which had been cultured in 10% serum
for 3 weeks demonstrated signiﬁcant staining for both
FGF-2 and perlecan (Fig. 5, FCS). Cells grown in ITS for
3 weeks showed less staining for perlecan, likely due to
the absence of TGF beta, present in serum, but still
accumulated signiﬁcant amounts of FGF-2 (Fig. 5, ITS).
The absence of FGF-2 in ITS culture medium means that
the FGF-2 must be made and secreted by the chondrocyte.
How the chondrocyte secretes FGF-2, in the absence of
a signal peptide, is subject to much debate, and is beyond
the scope of this paper.
MECHANICAL LOADING OF ALGINATE ENCAPSULATED
CHONDROCYTES INDUCES AN FGF-DEPENDENT
ACTIVATION OF ERK
We have previously shown that there is an FGF-2 depen-
dent activation of ERK when articular cartilage is cut or
loaded7,21. In these experiments, cyclical loading for 2 min
was sufﬁcient to activate the ERK pathway at a variety of
modest, non-injurious, loads. To see if loading would acti-
vate ERK in alginate encapsulated chondrocytes, cells
which had been cultured for 4 weeks in 10% serum, were
made into plugs, then loaded cyclically for 2 min (0.5 Hz,
0.01 MPa). Plugs were maintained at 37C for the times
speciﬁed, then dissolved on ice. Cells were lysed and im-
munoblotted for phosphorylated, and then total ERK. ERK
activation was apparent upon loading, but not in the un-
loaded controls, and persisted for 6 h following load
[Fig. 6(A) ‘encapsulated chondrocytes’]. This prolonged ac-
tivation of ERK following a 2 min load was similar to that
seen on loading rested cartilage explants (0.5 Hz,
0.13 MPa) [Fig. 6(A) ‘Explants’]. In both instances, ERK ac-
tivation had returned to baseline by 15 h (data not shown).
In another set of experiments we were also able tohuman cartilage were taken and incubated with primary antibodies to FGF-2 and perlecan as above. Sections were washed and incubated
with secondary FITC labelled antibodies (1:2000). Fluorescence signals were detected either alone (‘Perlecan’ and ‘FGF-2’), or ‘merged’ by
Ultraview confocal microscopy (C). Bar¼ 20 mm.
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Fig. 6. An FGF-dependent activation of ERK occurs when alginate encapsulated chondrocytes are loaded. Alginate encapsulated chondro-
cytes which had been cultured in 10% serum for 3 weeks were made into alginate plugs (see Methods), then serum starved for 2 h. Plugs were
then left untreated () or loaded (þ) for 2 min (0.01 MPa, 0.5 Hz). After 30 min chondrocytes were dissolved from the alginate (50 mM EDTA in
150 mM NaCl with 2% Na3VO4) on ice and lysates generated to immunoblot for phosphorylated ERK. The blot was stripped and reprobed for
total ERK (A, Encapsulated chondrocytes). Similar experiments were performed with porcine knee articular cartilage explants loaded for 2 min
(0.13 MPa, 0.5 Hz) (A, explants), and with alginate encapsulated chondrocytes grown for 3 weeks in ITS (B). To test the FGF-2 dependence of
ERK activation upon loading, alginate encapsulated chondrocytes which had been cultured for 4 weeks in 10% serum were pre-incubated with
either medium alone (control) or SB402451 (250 nM) for 48 h. Plugs were prepared as above, and were treated with either serum-free medium
(c), IL-1 (100 ng/ml), FGF-2 (100 ng/ml) or were loaded cyclically for 2 min (0.01 MPa, 0.5 Hz) (load). After 30 min, lysates were generated as
above for phosphorylated ERK and total ERK immunoblots (C). Rested cartilage explants were cyclically loaded with 0.032, 0.01 and
0.002 MPa for 2 min. Explants were lysed as above and immunoblotted for phosphorylated, then total ERK (D).
Control FCS ITS
Perlecan
FGF-2
Fig. 5. Accumulation of pericellular FGF-2 and perlecan in alginate encapsulated chondrocytes. Chondrocytes were digested from porcine
articular cartilage and encapsulated into alginate beads (see Methods). Beads were cultured in 10% serum or ITS for 3 weeks. In addition,
some freshly isolated chondrocytes were encapsulated into alginate, and cultured for 2 days in serum. At the end of the culture period, beads
were dissolved in EDTA, resuspended in a small volume of NaCl (150 mM) and then allowed to adhere to Lab-Tek II chamber slides. Cells
were immunostained for perlecan (1:1000) or FGF-2 (1:1000) using the peroxidase based ABC kit, as before. Bar¼ 100 mm.
759Osteoarthritis and Cartilage Vol. 15, No. 7demonstrate activation of ERK when alginate encapsulated
chondrocytes grown in ITS for 3 weeks were loaded
[Fig. 6(B)].
ERK activation in response to chondrocyte loading ap-
pears to be highly sensitive. To study this further we also
determined the minimum load able to activate this pathway.
We cyclically loaded resting cartilage explants for 2 min with
0.032, 0.01 or 0.002 MPa. ERK activation was apparent
when cartilage was loaded at 0.032 and 0.01 MPa, but
not at 0.002 MPa [Fig. 6(D)]. Interestingly, in this and other
experiments, we have not been able to detect any differ-
ences in the magnitude of ERK response with increasing
loads. This suggests that rather than there being a graded
response to load, there is a threshold above which ERK
activation occurs.
To conﬁrm that the ERK activation upon loading alginate
encapsulated chondrocytes was due to FGF-2, we repeated
the experiment in the presence of the FGF receptor inhibitor
SB402451 (250 nM). This inhibitor has been validated previ-
ously and is highly speciﬁc for FGFRs at this concentra-
tion21,41. Chondrocytes, encapsulated into alginate and
cultured for 4 weeks in 10% serum were made into plugs.
Plugs were either left untreated (C), stimulated with IL-1
(100 ng/ml), FGF-2 (100 ng/ml), or were cyclically loaded
for 2 min (0.5 Hz, 0.01 MPa). All samples were left at 37C
for a total of 30 min. Chondrocytes were lysed and immuno-
blotted as before. In the absence of the FGFR inhibitor, ERK
was activated by both exogenous FGF-2 and by loading, and
weakly by IL-1. In the presence of the FGFR inhibitor the re-
sponses to FGF-2 and loading were strongly suppressed,
whilst the response to IL-1, which activates ERK via a sepa-
rate pathway, was unaffected [Fig. 6(C)]. The results indicate
that the activation of ERK upon loading alginate encapsu-
lated cells was largely dependent upon FGF-2.
ERK ACTIVATION UPON LOADING IS DEPENDENT UPON
THE PERICELLULAR CONCENTRATION OF FGF-2
To conﬁrm that the ERK activation upon loading alginate
encapsulated chondrocytes was dependent upon pericellu-
lar FGF-2, rather than release of intracellular growth factor,
we generated chondrocytes with differing concentrations of
pericellular FGF-2 through manipulation of the culture con-
ditions. By this means we generated cells with no detect-
able immunostaining for pericellular FGF-2 (freshly
isolated cells as before), cells which had been cultured for
3 weeks in 10% serum which demonstrated modest FGF-
2 staining, and cells which had been cultured for 3 weeks
in 10% serum but which had also received exogenous re-
combinant FGF-2 for 3 days in week 2 of culture. These
cells accumulated signiﬁcantly more pericellular FGF-2 by
immunostaining [Fig. 7(A)]. When these cells were made
into plugs and loaded, ERK activation occurred only in
those cells that exhibited pericellular staining for FGF-2,
i.e. those cultured for 3 weeks in serum [Fig. 7(B), ‘10% se-
rum’ and ‘10% serum/FGF-2’]. Moreover, the ERK re-
sponse was increased in those cells where the pericellular
concentration of FGF-2 was greatest, i.e., those cultured
with recombinant FGF-2 [Fig. 7(B), ‘10% serum/FGF-2’].
Cells that had been freshly isolated from cartilage, and
which showed no immunostaining for FGF-2 failed to be-
come activated upon loading [Fig. 7(B), ‘control’]. All three
sets of chondrocytes were able to activate ERK normally
in response to recombinant FGF-2 indicating that FGFR ex-
pression was not affected by the different culture conditions.
There was also no indication that the cell numbers were dif-
ferent between the FGF treated and untreated cells asjudged by total ERK levels, although total ERK levels for
freshly isolated cells were consistently lower.
PROTEIN TYROSINE PHOSPHORYLATION OF PROTEINS
FOLLOWING LOADING IS MAINLY FGF DEPENDENT
Thus far, we have demonstrated that the ERK activation
upon loading articular chondrocytes is FGF dependent. To
determine whether other pathways might also be involved
in chondrocyte responses to loading, we studied the protein
tyrosine phosphorylation patterns of chondrocytes which
had been stimulated by FGF-2 or loading, in the presence
or absence of the FGFR inhibitor. IL-1 was also used to
control for the speciﬁcity of the inhibitor. Cell lysates were
prepared after 5, 15 and 30 min following stimulation, then
electrophoresed and immunoblotted with a phosphotyrosine
antibody. The blots were stripped and reprobed ﬁrstly for
phosphorylated ERK, then total ERK. Upon stimulation
with IL-1, FGF-2, or by loading a number of cellular proteins
showed increased tyrosine phosphorylation compared to
control at 5, 15 and 30 min. Fig. 8A shows the 15 min
time point. Close inspection of the autoradiographs showed
changes in at least 15 bands, ranging from 40 to 150 kDa.
The pattern of band induction was similar between FGF-2
and loading, although IL-1 also caused tyrosine phosphory-
lation of many of the same proteins. In the presence of
the FGFR inhibitor, the increase in protein tyrosine phos-
phorylation upon loading or FGF-2 stimulation was mark-
edly suppressed indicating that most of the early tyrosine
phosphorylation events upon loading were FGF dependent.
The IL-1 response was not blunted by the presence of the
FGFR inhibitor. A phosphorylated band/s migrating at ap-
proximately 150 kDa was strongly induced by loading or
IL-1, but was not suppressed by the FGFR inhibitor, indicat-
ing that additional, FGF-independent, pathways may also
be activated upon loading. Of the expected phosphorylated
proteins, the FGFR was not clearly visible as a discreet
phosphorylated band (expected to run at 110 kDa). Phos-
phorylated ERK was apparent only on stripping and re-
probing the membrane [Fig. 8(B)]. As expected, ERK acti-
vation upon stimulation with FGF-2 or loading was inhibited
by the FGFR inhibitor. At 15 min, ERK activation upon IL-1
stimulation was barely detectable. Even sample loading
was conﬁrmed by total ERK levels [Fig. 8(C)].
Discussion
We have shown that in articular cartilage FGF-2 binds to
the abundant HSPG perlecan, and that FGF-2 and perlecan
co-localise within the pericellular matrix of human and por-
cine chondrocytes. We have demonstrated that chon-
drocytes encapsulated in alginate are able to lay down
a pericellular matrix, and have uncovered a role for pericel-
lular FGF-2 in chondrocyte mechanotransduction.
By electron microscopy, the pericellular matrix of articular
cartilage is seen as a relatively lucent zone around chon-
drocytes, devoid of ﬁbrillar collagens. By immunohisto-
chemistry, this region is rich in type VI collagen and
excludes type II collagen26. Perlecan is known to be a peri-
cellular matrix protein in developmental and ovine articular
cartilages23e25, and is up-regulated in osteoarthritis27. We
have conﬁrmed its pericellular localisation in adult human
cartilage and also shown that it binds and co-localises
with FGF-2. In the superﬁcial layer of human cartilage, per-
lecan and FGF-2 formed laminar bands, which ran parallel
to the articular surface, and by inference, perpendicular to
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Fig. 7. ERK activation upon loading is dependent upon pericellular FGF-2. Alginate encapsulated chondrocytes were generated in three dif-
ferent ways: cells which had been freshly isolated and encapsulated for 2 days only (control), cells which had been encapsulated and cultured
in 10% serum for 3 weeks (10% serum), and cells which had been encapsulated and cultured in 10% serum for 3 weeks but in whom addi-
tional recombinant FGF-2 had been added to the culture for 3 days in week 2 (10% serum/FGF-2). At the end of the culture period some cells
were dissolved from alginate and immunostained for FGF-2 as before (A). The remainder of cells were made in to alginate plugs as before.
Plugs were either left untreated (C), stimulated with FGF-2 (100 ng/ml), or were loaded for 2 min (0.01 MPa, 0.5 Hz). Cell lysates were immu-
noblotted for phosphorylated and total ERK as before (B).
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Fig. 8. Protein tyrosine phosphorylation upon chondrocyte loading is mainly FGF-2 dependent. Chondrocytes were extracted from articular
cartilage, encapsulated into alginate beads, and cultured in 10% serum for 4 weeks. Forty-eight hours prior to loading some beads were in-
cubated with SB402451 (250 nM). Beads were made into plugs on the day of the experiment as described above. Plugs were treated with
either serum-free medium (C), IL-1 (100 ng/ml), FGF-2 (100 ng/ml), or were loaded (0.01 MPa, 0.5 Hz). After 15 min plugs were dissolved
with EDTA on ice and lysed. Lysates were run on 12.5% sodium dodecyl sulphate page, then immunoblotted with an anti-phosphotyrosine
antibody (1:3000) (A). The blots were stripped and reprobed ﬁrst for phosphorylated ERK (B), then total ERK (C).
761Osteoarthritis and Cartilage Vol. 15, No. 7an applied force. Disruption of this layer early in OA might
conceivably impair tissue responses to normal mechanical
loading.
Unlike that in the growth plate, where 75% of GAG chains
on perlecan are chondroitin sulphate28, perlecan in articular
cartilage (both young pig and human) is predominantly
substituted with heparan sulphate (data not shown), and it
is upon these GAG chains that FGF-2 is bound. Other cell
surface HSPGs such as CD44 and members of the synde-
can and glypican family, are expressed in articular chondro-
cytes29, but we found no evidence for other abundant
HSPGs apart from perlecan.
The sequestration of FGF-2 on perlecan within a few
microns of the cell surface makes it ideally placed to initiate
a rapid signalling response upon loading. (ERK activation
upon loading explants occurs within 2 min7). This might
occur as a result of release of FGF-2 from the matrix, either
detached or attached to HS, or exchange of FGF-2 from
perlecan to cell surface HSPGs. Alternatively, the close
proximity may allow presentation of FGF-2 to the FGF cell
surface receptor whilst still attached to perlecan. Perlecan
and heparan sulphate have been shown to be co-factors
for FGF receptor tyrosine kinase activation30e33, so it is
tempting to speculate that in addition to sequestering
FGF-2, perlecan may directly participate in the signalling
response upon loading. We hypothesise that in resting,
unloaded cartilage FGF-2 is held back from the cell surface
thereby preventing signal transduction through the FGF
receptor, but upon mechanical deformation of the matrix,
FGF-2 is presented to the cell surface receptor with bound
heparan sulphate, to activate down stream signalling
pathways.
The cyclic loading used in these experiments results in
a signiﬁcant time-averaged creep compression by the end
of the 2-min loading protocol (25% for alginate, 5% for ex-
plants). It may be that the ERK activation upon loading is
the result of the net static strain that occurs by the end of
the loading period. It is not clear whether the cyclic compo-
nent of the load or the speciﬁc loading frequency deter-
mines the tissue response.
FGF-2 has been implicated as a mechanotransducer in
other tissues. It was released by cultured adult rat ventricu-
lar myocytes in response to increased mechanical pres-
sure34, and by human skeletal muscle cells in response to
mechanical strain and sarcolemmal injury35. When smooth
muscle cells encapsulated in a 3D collagen gel were sub-
jected to a single compressive load a three fold increase
in thymidine incorporation occurred, which was inhibited
by neutralising antibodies to FGF-2 but not to platelet-
derived growth factor36. Pintucci et al. have described an
FGF-dependent activation of ERK in conﬂuent monolayer
endothelial cells wounded with a razor blade. Blocking
this response with neutralising antibodies to FGF-2 blocked
endothelial cell migration37. In order to address from which
location stored FGF-2 was liberated, Cheng et al.38 mea-
sured its release from cultured vascular endothelial cells
in response to mechanical strain. They determined that
most of the release was from intracellular rather than HS
bound stores.
Our results in alginate encapsulated chondrocytes are at
variance with the conclusions from the above studies in
other cell types. We have found that chondrocytes in algi-
nate lay down pericellular matrix upon which FGF-2 binds,
and in instances where little pericellular FGF-2 exists,
ERK responses to mechanical loading are attenuated. It is
possible that there may be additional release from intra-
cellular FGF-2 stores upon loading, but the most likelyinterpretation of the data is that the pericellular pool, rather
than release of intracellular growth factor, mediates FGF-2
dependent mechanotransduction in cartilage.
Finally, are integrins required for FGF mediated mecha-
notransduction in articular cartilage? As many tyrosine
kinase growth factor receptors are closely linked to integrins
on the cell surface and cooperate with growth factor signal-
ling39, 40, it is possible that they modulate FGFR signal
transduction upon loading. Our results suggest that most
protein tyrosine phosphorylation upon loading is FGF-2
dependent, although FGF-independent protein phosphory-
lation (at 150 kDa) indicates the possibility of additional
pathway activation. Whether this is mediated by integrin
ligation is currently unknown.
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